An antiviral transfer sheet manufacturing method, comprising: forming a functional layer including an inorganic antiviral agent powder and a hard coat agent on a base material sheet, wherein the hard coat agent is an active energy-ray curable resin or a thermally curable and active energy-ray curable resin, wherein the functional layer has a boundary surface in contact with the base material sheet, among the individual particles of the inorganic antiviral agent powder, the particles of which a part of the particle surface is in contact with the boundary surface are contact-effective powder particles, each contact-effective powder particle has an independent contact area in contact with the boundary surface, a total value of the independent contact areas of the contact-effective powder particles present in a certain section of the boundary surface is a total contact area, and a percentage of the total contact area with respect to an area of the certain section is a contact-effective powder-occupied percentage, the contact-effective powder-occupied percentage being determined as described in the description, characterized in that forming the functional layer comprises: disposing the inorganic antiviral agent powder on one surface of the base material sheet such that the contact-effective powder-occupied percentage is not less than 50% and not more than 80%, wherein the inorganic antiviral agent powder is disposed by applying a suspension of organic solvent containing the inorganic antiviral agent powder, and later removing the organic solvent, and positioning the hard coat agent from over the inorganic antiviral agent powder in layer shape, wherein an adhesive layer is formed on the functional layer, in contact with the functional layer or via another layer, the inorganic antiviral agent powder has an amount of not less than 0.01 g and not more than 0.03 g per 1 m 2 of the antiviral transfer sheet. forming a functional layer including an inorganic antiviral agent powder and a hard coat agent on a base material sheet, wherein the hard coat agent is an active energy-ray curable resin or a thermally curable and active energy-ray curable resin, wherein the functional layer has a boundary surface in contact with the base material sheet, among the individual particles of the inorganic antiviral agent powder, the particles of which a part of the particle surface is in contact with the boundary surface are contact-effective powder particles, each contact-effective powder particle has an independent contact area in contact with the boundary surface, a total value of the independent contact areas of the contact-effective powder particles present in a certain section of the boundary surface is a total contact area, and a percentage of the total contact area with respect to an area of the certain section is a contact-effective powder-occupied percentage, the contact-effective powder-occupied percentage being determined as described in the description, characterized in that forming the functional layer comprises: disposing the inorganic antiviral agent powder on one surface of the base material sheet such that the contact-effective powder-occupied percentage is not less than 50% and not more than 80%, wherein the inorganic antiviral agent powder is disposed by applying a suspension of organic solvent containing the inorganic antiviral agent powder, and later removing the organic solvent, and positioning the hard coat agent from over the inorganic antiviral agent powder in layer shape, wherein disposing the inorganic antiviral agent powder on one surface of the base material sheet such that the contact-effective powder-occupied percentage is not less than 50% and not more than 80%, wherein the inorganic antiviral agent powder is disposed by applying a suspension of organic solvent containing the inorganic antiviral agent powder, and later removing the organic solvent, and positioning the hard coat agent from over the inorganic antiviral agent powder in layer shape, wherein an adhesive layer is formed on the functional layer, in contact with the functional layer or via another layer, the inorganic antiviral agent powder has an amount of not less than 0.01 g and not more than 0.03 g per 1 m 2 of the antiviral transfer sheet.